Advertisement

Topics

SinuSys Corp. Company Profile

12:50 EDT 26th March 2019 | BioPortfolio

Chronic sinusitis affects more than 31 million people in the United States. It is more prevalent than heart disease and asthma, and has a greater impact on patients’ quality of life than chronic back pain or congestive heart failure. The U.S. healthcare system currently spends more than $8 billion annually on improving the health of patients with sinus conditions. However, approximately 20 percent of sinusitis patients do not experience adequate relief from current pharmaceutical treatments, which can have unpleasant side effects even when effective. For these patients, the most effective treatments to-date have been Functional Endoscopic Sinus Surgery (FESS) and high-pressure balloon dilation, which can cause significant patient discomfort and are conducted in a surgical suite under general anesthesia or IV sedation.


News Articles [76 Associated News Articles listed on BioPortfolio]

Helix BioPharma Corp. Board Changes

RICHMOND HILL, Ontario, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candi...

Emblem Corp. announces new board appointments

TORONTO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”) today announced the appointment of Connie A. Stefankiewicz and Loreto Grimaldi ...

RMMI Corp. Completes Initial Public Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS. CA...

Helix BioPharma Corp. Extends Annual Meeting Date

RICHMOND HILL, Ontario, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix”), an immuno-oncology company developing innovative drug candidates for the prevent...

RMMI Corp. to Commence Trading on the Canadian Securities Exchange

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS. CA...

Helix BioPharma Corp. Closes Third Tranche of Private Placement

RICHMOND HILL, Ontario, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candi...

International Cannabis Corp. Building Global Network -- CFN Media

SEATTLE, Nov. 21, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, ...

Helix BioPharma Corp. Extends Period to Exercise Warrants

RICHMOND HILL, Ontario, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the ...

PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

CORP: Partitional Calorimetry.

For thermal physiologists, calorimetry is an important methodological tool to assess human heat balance during heat or cold exposures. A whole-body direct calorimeter remains the gold standard instrum...

CORP: assessments of upper- and lower-limb muscle strength and voluntary activation in humans.

Muscle strength - the maximal force generating capacity of a muscle or group of muscles - is regularly assessed in physiological experiments and clinical trials. An understanding of the expected varia...

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Feasibility of a Minimally Invasive Thoracoscopic Ultrasound for Localization of Pulmonary Nodules

The ex-vivo lung will be evaluated by XLTF-UC180 for localization of the tumor. The ultrasound probe will be put on the lung surface in several different directions to obtain the cross sec...

Companies [42 Associated Companies listed on BioPortfolio]

SinuSys Corporation

SinuSys Corp. (www.sinusys.com) develops medical device therapies to improve the health of millions of patients suffering from chronic sinusitis worldwide. The company’s ...

SinuSys Corp.

Chronic sinusitis affects more than 31 million people in the United States. It is more prevalent than heart disease and asthma, and has a greater impact on patients’ quality ...

NORLOFF COMPUTER CORP

Nil

ATLANTIS DRUG CORP

Nil

Precision Engineered Products LLC

More Information about "SinuSys Corp." on BioPortfolio

We have published hundreds of SinuSys Corp. news stories on BioPortfolio along with dozens of SinuSys Corp. Clinical Trials and PubMed Articles about SinuSys Corp. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SinuSys Corp. Companies in our database. You can also find out about relevant SinuSys Corp. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Anesthesiology
An anesthesiologist (US English) or anaesthetist (British English) is a physician trained in anesthesia and perioperative medicine. Anesthesiologists are physicians who provide medical care to patients in a wide variety of (usually acute) situations. ...


Corporate Database Quicklinks



Searches Linking to this Company Record